These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27811211)

  • 1. Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging.
    Lessire S; Douxfils J; Pochet L; Dincq AS; Larock AS; Gourdin M; Dogné JM; Chatelain B; Mullier F
    Clin Appl Thromb Hemost; 2018 Jan; 24(1):129-138. PubMed ID: 27811211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of low plasma concentrations of apixaban in the periprocedural setting.
    Lessire S; Dincq AS; Siriez R; Pochet L; Sennesael AL; Vornicu O; Hardy M; Deceuninck O; Douxfils J; Mullier F
    Int J Lab Hematol; 2020 Aug; 42(4):394-402. PubMed ID: 32297711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
    Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
    Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of new methodologies for the chromogenic estimation of betrixaban concentrations in plasma.
    Siriez R; Evrard J; Dogné JM; Pochet L; Bouvy C; Lessire S; Mullier F; Douxfils J
    Int J Lab Hematol; 2019 Apr; 41(2):250-261. PubMed ID: 30604921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients.
    Jensen KOF; Hansen SH; Goetze JP; Jesting A; Stensballe J; Hansen H
    Eur J Haematol; 2017 Nov; 99(5):431-436. PubMed ID: 28833682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
    Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
    Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
    Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
    Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
    Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
    Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
    Yates SG; Smith S; Tharpe W; Shen YM; Sarode R
    Transfus Apher Sci; 2016 Oct; 55(2):212-215. PubMed ID: 27377884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk.
    Zhang Y; Qian Q; Qian G; Sun G
    Br J Biomed Sci; 2016 Jul; 73(3):134-139. PubMed ID: 27400196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
    Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
    Douxfils J; Chatelain B; Hjemdahl P; Devalet B; Sennesael AL; Wallemacq P; Rönquist-Nii Y; Pohanka A; Dogné JM; Mullier F
    Thromb Res; 2015 May; 135(5):852-60. PubMed ID: 25743887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization.
    Wiesen MHJ; Blaich C; Taubert M; Jennissen V; Streichert T; Pfister R; Michels G
    Eur J Clin Pharmacol; 2018 May; 74(5):611-618. PubMed ID: 29376194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
    Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
    Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
    Gosselin RC; Francart SJ; Hawes EM; Moll S; Dager WE; Adcock DM
    Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The edoxaban-M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma.
    Siriez R; Yildiz H; Bouvy C; Haguet H; Maloteau V; Hardy M; Mullier F; Dogné JM; Hainaut P; Douxfils J
    Res Pract Thromb Haemost; 2022 Mar; 6(3):e12680. PubMed ID: 35434470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation.
    Bloemen S; Zwaveling S; Mullier F; Douxfils J
    Thromb Res; 2019 Dec; 184():8-15. PubMed ID: 31677449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.